Equillium reports Q2 2026 results, plans Australia dossier filing for EQ504

Equillium, Inc. reported financial results for the quarter ended June 30, 2026, alongside a pipeline update centered on EQ504, described as its potent and selective aryl hydrocarbon receptor (AhR) modulator.¹

CEO Bruce Steel said the company's colon-targeted formulated product has been manufactured, and it plans to submit the dossier for its Phase 1 study in Australia imminently.¹ He said the study is expected to begin in the fourth quarter of 2026, with topline data reported approximately six months after that.¹ The study is designed, per Steel, as a conventional randomized, double-blind, placebo-controlled single and multiple ascending dose study (SAD/MAD) in healthy volunteers, focused on safety, tolerability, pharmacokinetics and pharmacodynamics to assess proof of mechanism.¹ If that data is supportive, Steel said the company anticipates expeditiously initiating a placebo-controlled study to assess the safety, tolerability, and efficacy of EQ504 in patients with moderately to severely active ulcerative colitis.¹

Beyond the lead program, Equillium said it initiated IND-enabling development activities for EQ504 as a potential inhaled therapy to treat inflammatory lung diseases.¹ It also said it started IND-enabling work for EQ302, an oral, bi-specific inhibitor targeting IL-15 and IL-21, aimed at celiac disease.¹ Separately, the company said it formed a Clinical Advisory Board chaired by Professor Bruce Sands, who leads the Feinstein IBD Clinical Center at Mount Sinai, to help guide the EQ504 ulcerative colitis clinical program.¹

On finances, Equillium ended the quarter with $57.2 million in cash and cash equivalents as of June 30, 2026, down from $61.3 million at March 31, 2026.¹ The company said this balance is expected to fund its currently planned operations into 2029.¹